In the latest trading session, Novo Nordisk (NVO) closed at $48.77, marking a +1.73% move from the p

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified wa

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities ar

Medicare GLP-1 coverage starts Wednesday. Here’s what patients should know about cost, eligibility a

Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a cop

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key dif

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it wort

Citi has said Novo Nordisk's (NYSE:NVO) Wegovy pill is outpacing its rivals in the United States, ev

I present my top 10 high-yield dividend stocks for July 2026, emphasizing margin of safety, attracti

Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

The Medicare GLP-1 Bridge program will be the first time eligible Medicare Part D patients will be a

Denmark's Novo Nordisk , the maker of weight-loss drug Wegovy, hopes insurance will cover more U.S.

White House denies reports Trump received Eli Lilly's unapproved obesity drug retatrutide throug

Novo-Nordisk shares are trading higher by more than 6% on Monday as GLP‑1 support initiatives aimed

As demand for GLP-1 medications continues to increase across the U.S., CVS Health® (NYSE:CVS) today

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s

Hims & Hers Health (NYSE: HIMS) shares are climbing after Barclays reiterated its bullish stance

Novo Nordisk investigates claims by cyber group FulcrumSec alleging a 1.3TB data theft after a faile

https://www.reuters.com/legal/government/hacking-group-claims-major-hack-novo-nordisk-attempted-25-m

https://www.reuters.com/world/novo-nordisk-seek-regulatory-approval-wegovy-pill-china-soon-says-ceo-

Medicare's GLP-1 rollout could overwhelm doctors as seniors rush for $50 weight-loss drugs.

Novo Nordisk wins U.K. approval for Wegovy pill, offering adults a daily oral weight-loss option bac

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-detai

https://ml-eu.globenewswire.com/Resource/Download/eb763000-5b1f-4433-9713-f86ae3f76643

Novo Nordisk reported positive diabetes and weight-loss data, advanced zenagamtide plans, and topped

Novo Nordisk exploring additional uses for obesity drug semaglutide, including potential for longevi

https://www.sec.gov/ix?doc=/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm

These changes build on Caremark's industry leading efforts as a pharmacy benefits manager to exp

https://www.ema.europa.eu/en/news/first-oral-glp-1-treatment-weight-management

https://ml-eu.globenewswire.com/Resource/Download/5a943d3a-b39e-4fbd-84fd-c5f7530146f5

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

The US Supreme Court turned away appeals from six pharmaceutical companies seeking to topple the Med

Democrat Sen. Peter Welch backs Trump's MFN drug pricing plan as bipartisan pressure over prescr

Novo Nordisk shares new Wegovy pill data showing sustained weight loss, improved physical function,

Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switch

Novo Nordisk said higher-dose Wegovy drove greater weight loss in obesity patients, with most reduct

Hims & Hers Health shares tank after disappointing Q1 results. Company raised 2026 revenue outlo

Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European

https://www.cellularintelligence.com/news/a-defining-moment-for-cellular-intelligence

Trump administration proposes new IVF benefits rule aimed at expanding employer fertility coverage a

CMS and Novo Nordisk will offer eligible Medicare patients Wegovy for obesity treatment at a $50 mon

Eli Lilly plans to invest $4.5 billion in Indiana, expanding its U.S. manufacturing footprint and su